Drugs / Tarcocimab tedromer
Tarcocimab tedromer
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03790852 | Dec 2018 → Jun 2021 | diabetic macular edema, retinal vein occlusion, wet macular degeneration | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04049266 | Oct 2019 → Nov 2021 | wet macular degeneration | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06556368 | Aug 2024 → Aug 2026 overdue | wet macular degeneration | Kodiak Sciences Inc | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05066230 | Sep 2021 → Aug 2023 | diabetic retinopathy | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04964089 | Jun 2021 → Mar 2023 | wet macular degeneration | Kodiak Sciences Inc | Completed | No outcome recorded |
| Phase 3 | NCT04611152 | Sep 2020 → May 2023 | diabetic macular edema | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04603937 | Sep 2020 → Apr 2023 | diabetic macular edema | Kodiak Sciences Inc | Terminated | No outcome recorded |
| Phase 3 | NCT04592419 | Sep 2020 → Jun 2022 | macular retinal edema, retinal vein occlusion | Kodiak Sciences Inc | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tarcocimab tedromer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06556368 ↗ |
| Known as | KSI-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04603937 ↗ |
| Known as | OG-1953 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095154 ↗ |
| Known as | Tarcocimab tedromere | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095154 ↗ |
| Known as | Tarcocimab tedromero | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095154 ↗ |
| Action | Inhibit | “KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate” NCT04049266 ↗ |
| Modality | Protein / enzyme biologic | “KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate” NCT04049266 ↗ |
| Route | Intravitreal | “Intravitreal injection” NCT03790852 ↗ |